About the Study

Solid Tumors: A study of CBL0137 for relapsed or refractory solid tumors

This study is for: • Part B1: - Patients who are between the ages of 1 and 21 years old - Who have been diagnosed with progressive (growing) or recurrent (has come back) diffuse intrinsic pontine glioma (DIPG) or other diffuse midline gliomas that has a mutation in the H3 K27M gene • Part B2: - Patients who are between the ages of 1 and 30 years old - Who have been diagnosed with osteoscaroma that has relapsed (has come back) or is refractory (has not responded to earlier treatment) The goal of this study is to find what effects, good and/or bad, the drug CBL0137 has on children and young adults with relapsed or refractory solid tumors. Note: Children's Mercy is not participating in Part A of this study.

Interested in learning more?

Full Study Name: PEPN2111